Melanie Call

Melanie Call is Obsidian’s Senior Vice President and Head of Program Development, where she leads program management across all internal and external programs at the company, including shepherding Obsidian’s lead candidate through investigational new drug-enabling studies. Ms. Call brings over 25 years of product development, program management and strategic planning experience across multiple therapeutic areas in cell therapy, protein and small molecule therapeutics, and drug delivery. Prior to joining Obsidian, Ms. Call led the Accelerating Center at the Cell and Gene Therapy Center at IQVIA. Prior to IQVIA, she was Vice President, Strategic Planning and Operations at ImmunoCellular Therapeutics, a company focused on the development of cell therapies in oncology. Previously, Ms. Call worked at Amgen for more than 20 years in product development and R&D project management. While at Amgen, she provided operational leadership for more than 20 cross-functional product development teams, creating and executing global strategic plans that included integrated project planning, product profile development and risk management. Ms. Call holds an MBA from Washington State University and a B.A. in zoology from the University of Idaho.